BIOS Capital Management’s Lantern Pharma LTRN Stock Holding History
Bought
Maintained
Sold
Other funds holding LTRN
CM
BIOS Capital Management's LTRN Position: Q3 2026 in Review
BIOS Capital Management reduced its Lantern Pharma (LTRN) stake by 5.4% in Q3 2026, selling an estimated $32.5K and leaving 235,895 shares worth $238K. The position accounts for 0.7% of the portfolio, ranked #5.
BIOS Capital Management first reported a position in LTRN in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.42M in Q3 2025. 42 funds tracked by Wall St. Rank hold LTRN as of Q3 2026.
- BIOS Capital Management held 235,895 shares of Lantern Pharma worth $238K as of Q3 2026.
- BIOS Capital Management sold 13,502 Lantern Pharma shares in Q3 2026, an estimated $32.5K.
- Lantern Pharma made up 0.7% of BIOS Capital Management's portfolio in Q3 2026, its #5 holding.
- BIOS Capital Management first reported a position in Lantern Pharma in Q4 2024 and has held it in 8 quarters since.
- BIOS Capital Management's Lantern Pharma position peaked at $4.42M in Q3 2025.
- 42 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2026.
Based on BIOS Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.